AMGN - Amgen Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
190.36
-1.19 (-0.62%)
At close: 4:00PM EST

190.36 0.00 (0.00%)
After hours: 4:55PM EST

Stock chart is not supported by your current browser
Previous Close191.55
Open192.03
Bid190.25 x 900
Ask191.00 x 200
Day's Range189.70 - 193.40
52 Week Range163.31 - 210.19
Volume2,772,139
Avg. Volume2,696,201
Market Cap121.301B
Beta (3Y Monthly)1.36
PE Ratio (TTM)59.34
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield5.28 (2.73%)
Ex-Dividend Date2018-11-15
1y Target EstN/A
Trade prices are not sourced from all markets
  • Migraine-Focused Biotech Has A Headache On Quarterly Losses
    Investor's Business Daily5 hours ago

    Migraine-Focused Biotech Has A Headache On Quarterly Losses

    Biohaven Pharmaceutical slumped to a three-week low Wednesday after the biotech reported greater-than-expected third-quarter losses.

  • See what the IHS Markit Score report has to say about Amgen Inc.
    Markit13 hours ago

    See what the IHS Markit Score report has to say about Amgen Inc.

    Amgen Inc NASDAQ/NGS:AMGN

  • GuruFocus.comyesterday

    Despite Lofty Price, Illumina May Still Be a Buy

    The company already had a dominant position in the fast-growing gene sequencing market before strengthening its position with the acquisition of Pacific Biosciences

  • Reuters2 days ago

    Express Scripts offers new formulary for lower list-price drugs

    Express Scripts Holding Co on Tuesday announced a new drug reimbursement list with lower U.S. prices for brand-name medications, as a way to encourage drugmakers to move away from paying rebates after a prescription is filled. The manager of prescription drug benefits for large corporate employers and government health plans said its new National Preferred Flex Formulary will be available as of Jan. 1 to all clients. Drug rebates have come under fire from the Trump Administration and consumer groups as patients find themselves paying much higher insurance co-payments and deductibles tied to a drug's sticker price.

  • Amgen (AMGN) Stock Moves -0.83%: What You Should Know
    Zacks2 days ago

    Amgen (AMGN) Stock Moves -0.83%: What You Should Know

    Amgen (AMGN) closed the most recent trading day at $191.56, moving -0.83% from the previous trading session.

  • TheStreet.com2 days ago

    Amgen Is Showing Independent Strength in a Bullish Sign for the Future

    Mad Money viewers Friday night got a long recommendation from Jim Cramer. Cramer said to look no further than drug maker Amgen Inc. Cramer said that Amgen is a well-run company with a solid balance sheet that includes $42 billion in cash.

  • Merck's (MRK) Keytruda Gets FDA Approval for Liver Cancer
    Zacks2 days ago

    Merck's (MRK) Keytruda Gets FDA Approval for Liver Cancer

    Merck's (MRK) Keytruda gains FDA approval for hepatocellular carcinoma (HCC) in patients previously treated with sorafenib.

  • CNBC3 days ago

    Investors are flocking to 'quality' stocks. Here's what that means for the market

    A grouping of such companies by Citi surfaced the likes of Walmart, McDonald's, Pfizer, Procter & Gamble, Amgen and Quest Diagnostics. While not predictive in itself, this pattern is one seen in the run-up to a bear market. Shares of quality companies have been outperforming the broad benchmarks — both before the October market correction and on the bounce of the past two weeks.

  • Better Buy: Amgen Inc. vs. Pfizer Inc.
    Motley Fool4 days ago

    Better Buy: Amgen Inc. vs. Pfizer Inc.

    Which big drugmaker is the better pick for long-term investors?

  • See what the IHS Markit Score report has to say about Amgen Inc.
    Markit5 days ago

    See what the IHS Markit Score report has to say about Amgen Inc.

    Amgen Inc NASDAQ/NGS:AMGN

  • CNBC5 days ago

    Cramer Remix: Next week's earnings could make or break how the Fed approaches rate hikes

    CNBC's Jim Cramer explains how a strong consumer snapshot could force an ugly reaction from the Fed. The "Mad Money" host also hears from the CEO of Funko, a company that makes popular big-headed dolls. In the lightning round, Cramer says the Fed has curbed his enthusiasm on some stocks.

  • Highly Rated 'Surgeon' For Biologic-Drug Makers Soars 85% In 2018
    Investor's Business Daily5 days ago

    Highly Rated 'Surgeon' For Biologic-Drug Makers Soars 85% In 2018

    Repligen stock is on a rampage this year as it outperforms broad medical-products stocks. The bioprocessing firm has completely transformed, its CEO says.

  • 6 Pharmaceutical Stocks to Buy After the Midterms
    InvestorPlace5 days ago

    6 Pharmaceutical Stocks to Buy After the Midterms

    Despite massive gains for the Democrats in the midterm elections in the House of Representatives and on the state level, the Republicans managed to hold onto the Senate. This is good for big pharmaceutical stocks (if bad for pharmaceutical users). Had the Democrats won both the House and Senate, scrutiny over drug pricing and the actions of the largest pharmaceutical companies would have resumed.

  • How Analysts View Alexion Stock
    Market Realist5 days ago

    How Analysts View Alexion Stock

    In November 2018, of the total 18 analysts covering Alexion Pharmaceuticals (ALXN), 16 analysts have given the stock a “buy” or higher rating, and two analysts have given it a “hold” rating. The mean rating for Alexion Pharmaceuticals stock is 1.83 with a target price of $163.29, implying an upside potential of 28.4% over Alexion Pharmaceuticals’ closing price of $127.18 on November 10, 2018.

  • Analyzing Alexion Pharmaceuticals’ Dicerna Collaboration
    Market Realist5 days ago

    Analyzing Alexion Pharmaceuticals’ Dicerna Collaboration

    In October 2018, Alexion Pharmaceuticals (ALXN) entered a collaboration with Dicerna Pharmaceuticals that provides Alexion exclusive worldwide licenses and development and commercial rights to two molecules for complement-mediated diseases along with an exclusive option for other molecules for two additional targets within the complement pathway. Under the collaboration, Alexion will make an upfront payment of $37.0 million and could be required to pay up to ~$625.0 million in milestone payments and royalties on product sales.

  • The Latest: Calif. shooting survivor was at Vegas massacre
    Associated Press6 days ago

    The Latest: Calif. shooting survivor was at Vegas massacre

    THOUSAND OAKS, Calif. (AP) — The Latest on the shooting at a Southern California bar that left 13 dead including the gunman (all times local):

  • Reuters6 days ago

    Coherus prices biosimilar to Amgen's Neulasta at 33 pct discount

    Coherus BioSciences Inc said on Thursday it would price its biosimilar to Amgen Inc's infection-fighting treatment, Neulasta, at a 33 percent discount. The list price of $4,175 per unit set by Coherus is the same as Mylan NV's biosimilar Fulphila that was approved earlier this year. Coherus intends to launch the biosimilar, Udenyca, on Jan. 3, it said on a conference call.

  • A Look at Alexion Pharmaceuticals’ Operational Performance
    Market Realist6 days ago

    A Look at Alexion Pharmaceuticals’ Operational Performance

    For fiscal 2018 and 2019, Alexion Pharmaceuticals’ gross margins are expected at 91.08% and 91.22%, respectively, as compared with gross margins of 91.95% for fiscal 2017. In comparison, fiscal 2018 gross margins for peers Abbott Laboratories (ABT), Amgen (AMGN), and Johnson & Johnson (JNJ) are expected at 59.29%, 85.73%, and 70.43%, respectively. Alexion Pharmaceuticals incurred selling, general, and administrative expenses of $258.7 million in the third quarter of 2018 as compared with $270.6 million in the third quarter of 2017.

  • Analyzing Alexion Pharmaceuticals’ Product Performance
    Market Realist6 days ago

    Analyzing Alexion Pharmaceuticals’ Product Performance

    Alexion Pharmaceuticals’ (ALXN) key products on the market include Soliris, Strensiq, and Kanuma. Total Soliris sales increased from $755.4 million in the third quarter of 2017 to $888.0 million in the latest quarter. Its US sales increased from $307.6 million in the third quarter of 2017 to $404.5 million in the latest quarter. Its Europe sales increased from $248.4 million in the third quarter of 2017 to $262.1 million in the latest quarter.

  • How Alexion Is Positioned in November
    Market Realist6 days ago

    How Alexion Is Positioned in November

    Alexion Pharmaceuticals (ALXN), a global biopharmaceutical company, is a leader in complement inhibition and is focused on the therapeutic areas of hematology, nephrology, neurology, and metabolic disorders. Alexion has brought to market the only approved complement inhibitor for paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and anti-acetylcholine receptor antibody-positive generalized myasthenia gravis. Further, the company has two enzyme replacement therapies for hypophosphatasia and lysosomal acid lipase deficiency.

  • Here's Why bluebird bio Fell 21.4% in October
    Motley Fool7 days ago

    Here's Why bluebird bio Fell 21.4% in October

    In September and October, investors thought Amgen set the bar in multiple myeloma too high, but in November bluebird bio teased promising data of its own.

  • 7 Healthcare Stocks Soaring on Election Results
    InvestorPlace7 days ago

    7 Healthcare Stocks Soaring on Election Results

    The company will next report results on Feb. 1 before the bell. Analysts are looking for earnings of $1.05 per share on revenues of $10.99 billion. When the company last reported on Oct. 25 earnings of $1.19 per share beat estimates by five cents on a 4.5% rise in revenues.

  • Investing.com7 days ago

    Amgen Rises 3%

    Investing.com - Amgen (NASDAQ:AMGN) rose by 3.06% to trade at $196.59 by 11:45 (16:45 GMT) on Wednesday on the NASDAQ exchange.

  • TheStreet.com7 days ago

    Drug Stocks Climb as Investors Digest Midterm Election Results

    Tuesday's midterm election results were welcome news for Big Pharma. Drug stocks rose on Wednesday, Nov. 7 amid perceptions that a divided Congress makes it less likely for major changes to occur in the drug-pricing environment in the U.S., analysts said. "Though we didn't view last night's outcome as removing all political risk to the group, it should make it more difficult to enact any major changes to the drug-pricing regime in America (which was already unlikely) and help improve investor sentiment, especially for the larger-caps," wrote biotech analysts at RBC Capital Markets LLC in a Wednesday note.

  • Amgen (AMGN) Counts on New Drugs Amid Rising Biosimilar Woes
    Zacks7 days ago

    Amgen (AMGN) Counts on New Drugs Amid Rising Biosimilar Woes

    Amgen's newer drugs, Prolia, Xgeva, Kyprolis, are driving sales. Lower sales of mature drugs like Enbrel and biosimilar competition for Neulasta/Epogen are concerns.